Influenza, commonly referred to as the flu, is an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the influenza viruses), that affects birds and mammals. The most common symptoms of the disease are chills, fever, sore throat, muscle pains, severe headache, coughing, weakness/fatigue and general discomfort. Sore throat, fever and coughs are the most frequent symptoms. In more serious cases, influenza causes pneumonia, which can be fatal, particularly for the young and the elderly. Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a much more severe disease than the common cold and is caused by a different type of virus. Influenza may produce nausea and vomiting, particularly in children, but these symptoms are more common in the unrelated gastroenteritis, which is sometimes called "stomach flu" or "24-hour flu".
Typically, influenza is transmitted through the air by coughs or sneezes, creating aerosols containing the virus. Influenza can also be transmitted by direct contact with bird droppings or nasal secretions, or through contact with contaminated surfaces. Airborne aerosols have been thought to cause most infections, although which means of transmission is most important is not absolutely clear. Influenza viruses can be inactivated by sunlight, disinfectants and detergents. As the virus can be inactivated by soap, frequent hand washing reduces the risk of infection.
In 2009, an outbreak of Swine Flu (H1N1) occurred worldwide. The virus that causes the disease originally only jumped from live pigs to humans who had direct contact with them, then evolved so that it could be passed from human to human. The virus is a “reassortant,” meaning a mix of genes from swine, bird, and human flu viruses.
H5N1, or "bird flu," is spread when wild birds pass the virus along birds that are raised for human consumption, for example, chicken, turkey, or ducks. The wild birds do not seem to exhibit symptoms from the virus, but the livestock that contract the virus do get sick. The virus is then passed to humans when they consume the tainted livestock. Human bodies do not have antibodies to bird flu and therefore most people must be hospitalized to fight the virus.
"Δ9-tetrahydrocannabinol (Δ9-THC) has been widely established as a modulator of host immune responses" writes the research team of the study "Modulation of Airway Responses to Influenza A/PR/8/34 by Δ9-Tetrahydrocannabinol in C57BL/6 Mice" at Michigan State University. "Accordingly, the objective of the present study was to examine the effects of Δ9-THC on the immune response within the lungs and associated changes in the morphology of the bronchiolar epithelium after one challenge with a nonlethal dose of the influenza virus A/PR/8 (PR8)." C57BL/6 mice were treated by an oral tube with Δ9-THC and/or vehicle (corn oil) for 5 consecutive days. On the 3rd day, 50 plaque-forming units of PR8 and/or vehicle (saline) were introduced intranasally 4 hours before the Δ9-THC exposure. The mice were killed 7 and 10 days post infection. The levels at which mRNA levels of viral hem agglutinin 1 (an allergic reaction type occurrence where cells become more compacted together to prevent foreign materials entering them) were increased in a dose-dependent manner with Δ9-THC treatment. The degree of inflammation and virus-induced mucous cell metaplasia (replacement of one differentiated cell type with another mature differentiated cell type) was reduced in Δ9-THC-treated mice by 10 days post infection.
http://www.webmd.com/cold-and-flu/flu-guide/understanding-bird-flu
http://www.webmd.com/cold-and-flu/flu-guide/swine-flu-faq-1
http://www.webmd.com/cold-and-flu/flu-guide/default.htm
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase in Sept 2014 (Dr. Bob was still at CBIS) and I made my last purchase in June 2017; just prior to the Hemp Seizure that F'k-up everything for CBIS going forward.
BUT, on 2017-01-09 CBIS Entered into 1 yr. Research Collaboration Agreement (RCA) with Dana Farber Cancer Institute (DFCI) to Develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers.
Then on 2018-01-18 1st Frontiers In Oncology Article: "Nano Particle Drone to Target Lung Cancer with Radio Sensitizers & Cannabis." - KILLING CANCER
And then again on 2018-02-02 CBIS expanded the RCA with DFCI for 5 yrs. (@ $1.8M) to develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers. That RCA agreement expired on 2023-02-02.
NOW, On 2023-02-02 the Expanded RCA with DFCI has ended. THE RESULTS ARE NOW KNOWN:
For the $1.8mil investment with DFCI, several Cancer Killing Formulations have been developed.
#1-6 Represents the drug formulations developed by DFCI during the 5yr RCA for treatment of the following cancers:
1. Skin Cancer
2. Breast Cancer
3. Brain Cancer
4. Kaposi's Sarcoma
5. Lung Cancer
6. Pancreatic Cancer
7. CBN Patent Valuation
#7 is the US Patent that was awarded to CBIS which describes the formulation used to treat certain neurological ailments such as ODD, ADD, etc.
On 2023-05-08 it was announced that GBXI signs the first 3 acquisitions for the GBXI Conglomerate (follow link below for details)
finance.yahoo.com/news/gbxi-advances-forward-signs…
Then On 2023-12-13 you posted the following: "GBXI Corporate Filings, Financials, and trading status has been delayed due to change of control filings and approvals. The Company has several options on the list for trading resumption as it pursues its regulatory approvals. The Company is pursuing the fastest path to trading first and will proceed down the list as it moves towards its ultimate goal of bringing all the GBXI conglomerate company shares back trading again.
QUESTION: Where are we toward the completion of this process?? 50% / 75% / 90% ????
--------
Some info that the I have found about a SPAC is as follows:
When does a SPAC become public?
--------------------------------------------
These types of transactions, most commonly where a SPAC acquires or merges with a private company, occur after, often many months or more than a year after, the SPAC has completed its own IPO. Unlike an operating company that becomes public through a traditional IPO, however, a SPAC is a shell company when it becomes public.
Period to consummate the initial business combination.
--------------------------------------------------------------------
A SPAC will typically provide for a two-year period to identify and complete an initial business combination transaction. However, some SPACs have opted for shorter periods, such as 18 months. The SPAC’s governing instruments may permit it to extend that time period. If a SPAC seeks to extend the time period, it may be required to seek shareholder approval. If a SPAC lists its securities on an exchange, it is required to complete an initial business combination within three years of its IPO. IPO proceeds are held in the trust account until a SPAC consummates a business combination or liquidates. If the SPAC is liquidated, shareholders at the time of the liquidation will be entitled to their pro rata share of the aggregate amount then on deposit in the trust account.
On 2023-11-08 an independent entity named Capizate, Inc.; prepared and presented a "Situation Analysis of the GBX International Group" which provided a list of Strengths, Areas of Improvements, and a Cancer Drug Valuation of just one of the drug formulations noted above ($25Mil-$29Mil) - Impressive.
However, here is the list that I have concern for; can't go PUBLIC without being fixed:
Areas for improvement
----------------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
QUESTIONS:
---------------
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Thank you Raymond in advance of your response.
Best Regards
Show more
CBIS’s beautiful, state-of-the-art, retail facilities are designed to connect Cannabis Science directly with patients and doctors. They showcase...
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
1. Original CBIS, everyone has... Show more 20 hours 54 minutes ago
“We... Show more 3 hours 38 minutes ago